Conditions
Small Cell Lung Cancer
Trial Purpose
Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. MK-6070 is a new type of immunotherapy that uses a person’s immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a medication which binds to specific targets on cancer cells and delivers treatment to destroy those cells. Researchers want to know if giving MK-6070 and/or I-DXd can treat SCLC that did not respond or stopped responding to the first treatment.
The goals of this study are to learn:
* If gocatamig and I-DXd are safe and well tolerated
* If people who receive MK-6070 and I-DXd have their SCLC get smaller or go away
NATIONAL TRIAL REFERENCE NUMBER
NCT06780137
EU CT
2024-517926-25-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
Resources
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
About The Trial
Trial Phase
Trial Phase 1
Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.
Trial Phase 2
Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.
Trial start and end dates
- Actual study start date 27 February 2025
- Estimated primary completion date 31 October 2028
- Estimated study completion date 31 October 2028
Trial locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
Taking part in a clinical trial is an important decision
If you are considering joining a clinical trial, first learn as much as you can about:
- The investigational treatment that is being studied
- What the risks and possible benefits are for participants
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about